Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3133376
Max Phase: Preclinical
Molecular Formula: C64H85N19O16S4
Molecular Weight: 1504.77
Molecule Type: Protein
Associated Items:
ID: ALA3133376
Max Phase: Preclinical
Molecular Formula: C64H85N19O16S4
Molecular Weight: 1504.77
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@H](CCC(=O)O)NC1=O)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H](C)C(=O)N[C@H](C(N)=O)CSSC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N2
Standard InChI: InChI=1S/C64H85N19O16S4/c1-6-30(2)51-64(99)75-42(15-16-50(85)86)57(92)78-45(19-36-22-67-28-70-36)60(95)79-46(20-37-23-68-29-71-37)61(96)81-48-26-102-103-27-49(63(98)83-51)82-59(94)43(17-34-11-13-38(84)14-12-34)76-54(89)32(4)72-53(88)31(3)73-56(91)40(65)24-100-101-25-47(52(66)87)80-55(90)33(5)74-58(93)44(77-62(48)97)18-35-21-69-41-10-8-7-9-39(35)41/h7-14,21-23,28-33,40,42-49,51,69,84H,6,15-20,24-27,65H2,1-5H3,(H2,66,87)(H,67,70)(H,68,71)(H,72,88)(H,73,91)(H,74,93)(H,75,99)(H,76,89)(H,77,97)(H,78,92)(H,79,95)(H,80,90)(H,81,96)(H,82,94)(H,83,98)(H,85,86)/t30-,31-,32-,33-,40-,42-,43-,44-,45-,46-,47-,48-,49-,51-/m0/s1
Standard InChI Key: CSJQBWRBRLXMTL-ZWJMCFBWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1504.77 | Molecular Weight (Monoisotopic): 1503.5305 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Meinander K, Weisell J, Pakkala M, Tadd AC, Hekim C, Kallionpaa R, Widell K, Stenman U, Koistinen H, Narvanen A, Vepsalainen J, Luthman K, Wallen EAA. (2013) Pseudopeptides with a centrally positioned alkene-based disulphide bridge mimetic stimulate kallikrein-related peptidase 3 activity, 4 (3): [10.1039/C3MD20292E] |
Source(1):